title: Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation.
abstract: Previous studies have found that soluble urokinase plasminogen activation receptor (suPAR) increases during inflammatory and malignant illness and elevated suPAR levels may be associated with poor clinical outcome. The purpose of this study was to investigate plasma levels of suPAR during the course of allogeneic stem cell transplantation (SCT). Twenty SCT patients were included in the study. suPAR was measured by ELISA in daily taken plasma samples during the pretransplant conditioning with chemotherapy and weekly for 1 month after infusion of the graft. suPAR levels before the start of the conditioning were significantly elevated when compared to those of healthy controls. During the conditioning in particular treatment with antithymocyte globulin was associated with significantly increased suPAR levels (P = 0.012). At day +7 after infusion of the graft, suPAR levels had decreased to pretreatment levels. High suPAR levels at day 0 were associated with increased mortality (P = 0.011). The present study found increased suPAR levels during the conditioning in SCT patients. Further, the data indicated that increased suPAR levels may be associated with increased mortality, suggesting suPAR as a candidate for further studies as an outcome predictor in SCT.
authors.affiliation: Department of Clinical Immunology, the Blood Bank, the National University Hospital, Copenhagen, Denmark. ehaastrup@hotmail.com
authors.forename: E
authors.initials: E
authors.lastname: Haastrup
authors.forename: J
authors.initials: J
authors.lastname: Andersen
authors.forename: S R
authors.initials: SR
authors.lastname: Ostrowski
authors.forename: G
authors.initials: G
authors.lastname: Høyer-Hansen
authors.forename: N
authors.initials: N
authors.lastname: Jacobsen
authors.forename: C
authors.initials: C
authors.lastname: Heilmann
authors.forename: H
authors.initials: H
authors.lastname: Ullum
authors.forename: K
authors.initials: K
authors.lastname: Müller
mesh_terms: D000328:Adult; D000740:Anemia / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D000961:Antilymphocyte Serum / Q000494:pharmacology / Q000627:therapeutic use; D001769:Blood / Q000187:drug effects; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D019337:Hematologic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D053208:Kaplan-Meier Estimate; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011379:Prognosis; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood / Q000175:diagnosis / Q000628:therapy
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; C524898:PLAUR protein, human; D055293:Receptors, Urokinase Plasminogen Activator